Stifel on Immunovant (IMVT): 'upcoming data for Batoclimab in MG/CIDP (1Q25) remain important catalysts for the stock'
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $52.00 price target on Immunovant (NASDAQ: IMVT).The analyst comments "Granular data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
